GenEng News  Jul 3  Comment 
Aveo Pharmaceuticals and Novartis are at odds over how to end a three-year-old, up-to-$326 million exclusive worldwide license agreement to develop and commercialize Aveo’s humanized inhibitory antibody targeting growth differentiation factor 15...
FiercePharma  Jul 3  Comment 
Amgen and Novartis’ Aimovig, first in its new class of migraine drugs, hit the scene in May. And patients were ready for it: so much so that its makers are now overwhelmed in trying to meet initial interest, according to one analyst.
FierceBiotech  Jul 3  Comment 
Novartis has walked away from Aveo Pharmaceuticals’ AV-380 three years after paying $15 million (€13 million) upfront for the asset. The action cuts short a relationship that was starting to sour amid the slow progress of the treatment for...
Yahoo  Jul 3  Comment 
Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.
Benzinga  Jul 2  Comment 
Shares of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) soared higher by 60 percent early Monday morning in reaction to a new partnership with Novartis AG (ADR) (NYSE: NVS). What Happened Adamis, a specialty biopharmaceutical company that...
Wall Street Journal  Jul 2  Comment 
Adamis Pharmaceuticals agreed to sell the U.S. commercial rights for Symjepi, an epinephrine injector for the emergency treatment of allergic reactions, to Sandoz, a Novartis subsidiary.
Channel News Asia  Jun 30  Comment 
The chairman of Swiss drugmaker Novartis expects Alcon to be valued at between US$20 billion and US$30 billion when the opthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft.
Financial Times  Jun 29  Comment 
Foresight has not been the Swiss drug manufacturer’s forte


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki